HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany Shuts The Door On Switches

Executive Summary

Two prescription-to-OTC switch applications rejected by Germany’s Expert Committee for Prescription: preparations containing a combination of ibuprofen and phenylephrine hydrochloride and hydrocortisone 1% for external use.

Advertisement

Related Content

‘No Pain, No Gain’ in Germany’s OTC Market: Pain-Relief Launches From GSK and Fysioline, Aspirin Complex Returns
Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches
Germany Begins The Year With Two Possible Rx-To-OTC Switches
An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process
An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process
Zovirax launched OTC in Germany

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS148625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel